Andesa Financial Management Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 6.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,636 shares of the biopharmaceutical company’s stock after acquiring an additional 1,226 shares during the quarter. Andesa Financial Management Inc.’s holdings in Pfizer were worth $785,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. boosted its position in shares of Pfizer by 23.3% in the 2nd quarter. Steigerwald Gordon & Koch Inc. now owns 9,604 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 1,818 shares in the last quarter. Moody Aldrich Partners LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $154,045,000. Chicago Partners Investment Group LLC boosted its position in shares of Pfizer by 13.2% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 42,996 shares of the biopharmaceutical company’s stock worth $1,560,000 after purchasing an additional 5,018 shares in the last quarter. Truvestments Capital LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $1,139,000. Finally, Farmers National Bank boosted its position in shares of Pfizer by 4.3% in the 2nd quarter. Farmers National Bank now owns 120,730 shares of the biopharmaceutical company’s stock worth $4,380,000 after purchasing an additional 5,031 shares in the last quarter. Institutional investors and hedge funds own 69.42% of the company’s stock.
In other news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction on Monday, October 15th. The stock was bought at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the transaction, the insider now owns 21,976,484 shares in the company, valued at approximately $395,576,712. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.
Shares of PFE opened at $43.92 on Monday. Pfizer Inc. has a one year low of $33.20 and a one year high of $46.47. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market cap of $261.45 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.19 and a beta of 0.88.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The company had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The firm’s revenue was up 1.0% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 3 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Friday, November 9th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.10%. Pfizer’s dividend payout ratio is currently 51.32%.
A number of research firms have recently weighed in on PFE. Cantor Fitzgerald set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 27th. Credit Suisse Group set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, August 28th. Deutsche Bank set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 21st. JPMorgan Chase & Co. reissued a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a research report on Thursday, August 23rd. Finally, Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $43.27.
WARNING: “Andesa Financial Management Inc. Has $785,000 Stake in Pfizer Inc. (PFE)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/10/andesa-financial-management-inc-has-785000-stake-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: What is Cost of Capital?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.